Based on the link between obesity and AEH/EC, we hypothesized that the combination of a GLP-1R agonist and levonorgestrel would be useful as a novel treatment or prevention regimen and tested this hypothesis in preclinical models using EC cell lines and patient-derived organoids. The gene discussed is GLP1R; the disease is obesity disorder.